Makers of generic and brand-name drugs are set for arguments March 25 in a Supreme Court case in which federal officials argue that drug prices would be reduced without patent settlements. The case "will define how an entire industry does business," Generic Pharmaceutical Association President Ralph Neas said. An unfavorable ruling will be bad for drugmakers, taxpayers and consumers, he said.

Related Summaries